Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

NCT02317991 PHASE2 COMPLETED Results posted

The purpose of this study is to determine whether nab-Paclitaxel (Abraxane®) and ramucirumab (Cyramza®) are effective when used in combination for treating patients with metastatic gastroesophageal cancer who have either progressed or not responded to prior therapy.

Details

Lead sponsor	SCRI Development Innovations, LLC
Phase	PHASE2
Status	COMPLETED
Enrolment	65
Start date	Tue May 05 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri May 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Gastroesophageal Cancer

Interventions

• nab-paclitaxel
• ramucirumab

Countries

United States